TF2B

TF2B has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Oct 27, 2026: “Theaflavin monomers extend Caenorhabditis elegans lifespan through insulin/IGF-1 signaling pathway”.

Intervention

1 paper studies it2 findingsUpdated

1 new paper in 30 daysSee all 1 papers on TF2B

At a glance

The findings reach worms or flies, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Worms or flies: a single group. Cells, mice and humans: nothing yet.
  • 1 lab in 1 country
  • Funder: Guangdong Provincial Department of Science and Technology
  • Model organisms1

What did studies of TF2B find?

2

Studies of TF2B measured 2 outcomes: insulin/IGF-1 signaling and lifespan.

Insulin/IGF-1 signaling

downin worms1

1 study
  1. TF2B inhibits insulin/IGF-1 signaling in worms.

    “Mechanistically, TF1 and TF2B suppressed the DAF-2-mediated insulin/IGF-1 signaling pathway.”

    Model organisms

    Theaflavin monomers extend Caenorhabditis elegans lifespan through insulin/IGF-1 signaling pathway

    Journal of Functional Foods

More on Insulin/IGF-1 signaling

Lifespan

upin worms1

1 study
  1. TF2B extends lifespan in worms.

    “100 μM TF1 and 500 μM TF2B markedly increased lifespan”

    Model organisms500 μM

    Theaflavin monomers extend Caenorhabditis elegans lifespan through insulin/IGF-1 signaling pathway

    Journal of Functional Foods

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months